Abstract:Background: While soft tissue sarcomas (STSs) are rare tumors, liposarcomas are among the most common type of STS and are divided into four main subtypes: atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS); dedifferentiated liposarcoma (DDLPS); myxoid/round cell liposarcoma (MLPS); and pleomorphic liposarcoma (PLPS). The four different subtypes of liposarcomas have varying underlying molecular pathology, clinical behavior, and treatment sensitivity. Summary: Surgical resection is the mainstay of treatment for patients with localized liposarcoma. Radiotherapy is often used in conjunction with surgery for improving local control of liposarcoma, with MLPS being the most radiosensitive of the four subtypes. For unresectable, advanced, or metastatic disease, the effectiveness of chemotherapy can vary by subtype, with MLPS and PLPS being considered to be chemo-sensitive; however, median survival is low at around 2-years. Current first-line treatment options for patients with liposarcoma include local treatment with or without doxorubicin, ifosfamide, or a doxorubicin-ifosfamide combination; while second-line (and beyond) treatment options include ifosfamide, gemcitabine-based combinations, trabectedin, eribulin and possibly pazopanib as established therapies. A number of other experimental treatment options are being evaluated, including mouse double minute 2 homolog (MDM2) inhibitors, cyclin-dependent kinase (CDK)4/6 inhibitors, immune checkpoint modulators, nuclear export inhibitors, multi-kinase inhibitors, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, or various combinations regimens. This review discusses established systemic therapies and experimental treatment options for the treatment of patients with liposarcoma. Key message: New treatments are needed to effectively treat liposarcomas. Results from emerging and ongoing experimental therapeutic options will further define the role that these new treatments will play in the management of the different subtypes of liposarcoma.

Advances in the targeted therapy of liposarcoma.

New targeted therapies in liposarcoma: state of art and future perspectives

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection

Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges

Liposarcoma and Its Treatment

Established and experimental systemic treatment options for advanced liposarcoma

An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies

Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment

Liposarcoma: A Journey into a Rare Tumor's Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies

Management of Retroperitoneal Liposarcoma: A Case Report and Review of the Literature.

Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma

Case Report: Pathological Complete Response to Perioperative Treatment of Radiotherapy Combined with Angiogenesis Inhibitor in a Patient with Pleomorphic Liposarcoma.

Advances in molecular targeted therapy for soft tissue sarcomas

Breast Liposarcoma with Solitary Metastasis to the Pleura: A Case Report.

Pleomorphic Liposarcoma Unraveled: Investigating Histopathological and Immunohistochemical Markers for Tailored Diagnosis and Therapeutic Innovations

Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.

Analysis of prognostic factors and the effect of adjuvant radiother-apy and chemotherapy for liposarcoma of the extremities

The Future of Targeted Therapy for Leiomyosarcoma

Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma

Diagnosis and Treatment of Myxoid Liposarcoma